1. What drugs do hypertension patients take in clinical practice? Structure of antihypertensive drugs in a large siberian region
- Author
-
Y. I. Grinshtein, M. M. Petrova, V. V. Shabalin, R. R. Ruf, N. V. Topolskaya, A. A. Kosinova, and A. Y. Shtrikh
- Subjects
arterial hypertension ,antihypertensive drugs ,combination antihypertensive therapy ,Medicine - Abstract
Objective. To assess the frequency of prescribing of different groups of antihypertensive drugs (AHD) in the treatment of patients with arterial hypertension (AH) among patients of the Krasnoyarsk territory according to the Russian epidemiological studies ESSE-RF.Materials and methods. 1,603 persons aged 25–64 years, selected through systematic stratified multistage randomization among the population attached to the four outpatient clinics of Krasnoyarsk and Berezovsky district hospital were studied. All included subjects were subjected to a detailed survey of office blood pressure measurements. Results. The proportion of those on monotherapy was 53.4%. The most commonly accepted AHD, including in the combination therapy, were angiotensin-converting enzyme inhibitors (ACEI) – in 51% of cases, beta-blockers – 28.9 percent, angiotensin receptor blockers (ARBS) – 25,2%, diuretics – 23,2%, calcium channel blockers (CCB) – 11.9%, central action drugs – 2.0% and alpha-blockers – 0.4 percent. Beta-blockers often were taken by those of younger age – 38.1 per cent, mainly men aged 25–34 years (50.0 per cent). Among the combinations of AHD the most frequently encountered combination was ACEI + diuretic (6,8%), followed by rthe frequency of prescription by ARBS + diuretic, beta-blocker + diuretics, ARBS + CCB, ACE-I + CCB.Conclusion. The frequent prescription of ACE inhibitors and insignificant use of central action is noted. The high level of violence of use of AHD monotherapy in patients with hypertension (53,4%) is alarming, which may be one of the reason for the relatively low efficiency of antihypertensive therapy (31.6 percent). Beta-blockers were indicated unreasonably often for young men with hypertension aged 25–34 years.
- Published
- 2016
- Full Text
- View/download PDF